Tran et al [26] reported that the PD-1/PD-L1 inhibition by anti-PD-L1 antibody could synergize cisplatin enhance the anti-tumor efficacy in head and neck squamous cell carcinoma. Here, PDCD1 is linked to head and neck squamous cell carcinoma.